Sino Biopharmaceutical Limited provided group earnings guidance for the year ended 31 December 2021. The board of directors of the company informed the securities holders of the company and potential investors that the Group's profit attributable to the owners of the parent for the year ended 31 December 2021 is expected to increase by over 4 folds as compared to last year to more than approximately RMB 14,000 million (profit attributable to the owners of the parent for last year was RMB 2,771 million).